Schorno Dean L's Form 4 filing
Rigel Pharmaceuticals Inc (RIGL) · filed Feb 6, 2024
- Accession no.
- 0000905148-24-000446
- Filed
- Feb 6, 2024
- Trade date
- Feb 2-5, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $14.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schorno Dean LCIK 0001509688 | Officer (EVP & Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2024 | Common Stock | SSaleDisposed | −5,601 | $1.13F2 | −$6,329.13 | 409,918 | Direct | |
| Feb 5, 2024 | Common Stock | SSaleDisposed | −7,027 | $1.14 | −$8,010.78 | 402,891 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $1.1228 to $1.13. Upon request, the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission staff, full information regarding the shares sold at each such separate price.
Referenced by the price of 1 transaction in Table I.